Treatment Safety, Supply and Access

The safety and supply of treatment products is a key concern for the bleeding disorders community.

Since the 1970's and 1980's, when many people in our community were infected with human immunodeficiency virus (HIV) and hepatitis C (HCV) through the use of clotting factor concentrates, WFH has made it a priority to closely monitor product safety, supply, and access. The WFH issues advisories related to treatment safety and supply. We also monitor the development and regulatory status of new and novel treatments.